Long term outcomes after repeat lymph node dissections for persistent or recurrent differentiated thyroid cancer - 13/12/24
Abstract |
Background |
The primary treatment for locoregional recurrent/persistent differentiated thyroid cancer (DTC) is repeated lymph node dissection; however, there are limited reports on the safety and long-term efficacy of multiple operations.
Methods |
Patients who underwent a cervical lymph node dissection between 1998 and 2022 were included in this study. Demographics, initial thyroid surgery, subsequent lymph node dissections, follow up information, and response to therapy were acquired.
Results |
After one, two, three and four re-operations, 112/314 (35.7 %), 16/79 (20.3 %), 3/25 (12 %), and 0/3 (0 %) patients (p < 0.001) had an excellent response, respectively, resulting in a cumulative rate of 41.7 % (131/314). The risk for permanent hypoparathyroidism (2.9 %) or recurrent laryngeal nerve injury (2.2 %) was 5.1 % (14/272). This was higher in patients undergoing re-operative central neck dissection (CNDx) (8.7 %, 10/114) versus those who did not undergo a previous CNDx (2.5 %, 4/158, p < 0.02).
Conclusions |
Surgery remains the primary treatment for recurrent/persistent DTC, however, the likelihood of an excellent response decreases with additional operations. The risk of permanent complications is low but is more likely to occur during redo CNDx.
El texto completo de este artículo está disponible en PDF.Highlights |
• | The likelihood of an excellent response for thyroid cancer decreases with each additional cervical lymph node operation. |
• | The overall risk for permanent hypoparathyroidism (2.9 %) or recurrent laryngeal nerve injury (2.2 %) was 5.1 %. |
• | The risk of these complications was higher in patients undergoing re-operative central neck dissection. |
Keywords : Thyroid cancer, Neck dissection, Response to therapy
Esquema
Vol 239
Artículo 116045- janvier 2025 Regresar al número
Artículo precedente
- Healthcare disparities in access to surgical management and outcomes of patients with nonmetastatic primary liver cancer: A population based study from Louisiana tumor registry
- McKenzie Hargis, Aimée Galatas, Denise Danos, Hannah R. Malinosky, Sydney McManus, Kevin Sullivan, Mohammad Al Efishat, John Lyons, James C. Watson, Mary Maluccio, Omeed Moaven
- Examining the false-negative rate of a negative axillary node ultrasound-guided core needle biopsy in breast cancer patients undergoing upfront surgery
- Christine Rogers, Sarah Zeien, Kaleen Puccetti, Julie M. Jorns, Amanda L. Kong, Solomon Cherian, Chandler S. Cortina
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
¿Ya suscrito a @@106933@@ revista ?